CT Colonography and Stool DNA
Fail to Make USPSTF A-List
CT colonography and stool DNA failed to get on the list of preferred tools for screening for colorectal cancer.
A draft guideline from the U.S. Preventive Services Task Force released Oct. 6 calls for using one of three strategies:
• Fecal immunochemical test or high-sensitivity guaiac-based fecal occult blood test every year;
• Flexible sigmoidoscopy every ten years, plus FIT every year; or
• Colonoscopy every ten years.
Collins to Congress: A Flat, Year-long CR Would Be “Devastating” to NIH Research
If Congress passes another year-long, flat-funding resolution, the effect on NIH “would be simply devastating,” Director Francis Collins told a Senate appropriations subcommittee during a hearing Oct. 7.
“I can’t emphasize enough how much we are worried about this,” Collins said, sitting alongside NCI Acting Director Douglas Lowy and other institute directors.
CMS Issues Updated Pricing For Clinical Lab Fee Schedule
Centers for Medicare and Medicaid Services issued updated pricing determinations for the Clinical Laboratory Fee Schedule, which reversed a payment cut for the Oncotype DX breast cancer test.
Letter to the Editor from the Coalition for 21st Century Medicine
We are writing to clarify a few points in your Oct. 2 article, “CMS to Trim Spending on Diagnostic Lab Tests,” as it mistakenly intertwines two issues.
Tomas Lindahl, Paul Modrich, and Aziz Sancar win the Nobel Prize
Alexander Eggermont’s directorship of Institut Gustave Roussy extended by 5 years
Victoria Seewaldt joins City of Hope
NYU Langone names Shohei Koide to lead new biologics research program
Memorial Sloan Kettering and Cornell University to launch nanomedicine center
Oncology Nursing Society launches clinical resource platform
SWOG to fund Veterans Affairs Department medical centers
|Drugs and Targets|
FDA grants breakthrough therapy designation to abemaciclib in breast cancer
Merck and Bionomics Ltd. extend collaboration
Immunovia and OHSU form pancreatic cancer collaboration
MD Anderson and Theraclone Sciences launch OncoResponse company